Does PPI therapy predispose to Clostridium difficile infection?
Clostridium difficile infection (CDI) has emerged as a problem of epidemic proportions. Previous exposure to broad-spectrum antibiotics remains the most important predisposing factor for the disease. However, PPIs are increasingly being overprescribed and recent research has, therefore, focused on the association between PPI therapy and CDI. While the data remain observational, increasing evidence exists for at least a modest association between PPI use and CDI.
Pant
Chaitanya
C
Louisiana State University Health Sciences Center and Overton Brooks VA Medical Center, Shreveport, LA, USA.
Madonia
Phillip
P
Minocha
Anil
A
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D016360:Clostridioides difficile; D004761:Enterocolitis, Pseudomembranous / Q000453:epidemiology / Q000209:etiology*; D004941:Esophagitis / Q000188:drug therapy / Q000378:metabolism; D005744:Gastric Acid / Q000378:metabolism; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy / Q000378:metabolism; D054328:Proton Pump Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors